Movement Alert｜Natera Rises 3.18% in Regular Trading, Multiple Investment Banks Significantly Raise Price Targets

Market Focus09-17

On September 17, Natera rose 3.18% in regular trading, trading at $355.63/share, with turnover of $34.66 million.

On the news front, multiple investment banks recently raised their price targets on Natera in quick succession. UBS significantly raised its target from $290 to $435 while maintaining a Buy rating, and Rothschild & Co Redburn initiated coverage with a Buy rating and a $385 price target. Earlier, RBC Capital also lifted its target from $275 to $350, maintaining an Outperform rating. The consensus mean target now stands at approximately $344.

The upgraded outlooks are underpinned by a series of commercial milestones for Natera's Signatera molecular residual disease test, including FDA approval as a companion diagnostic in muscle-invasive bladder cancer, regulatory clearance from Japan's PMDA for colorectal cancer use, and EU IVDR Class C certification across multiple solid tumor types. Additionally, the company's Q2 revenue of $752.8 million significantly beat the $661.2 million estimate, prompting management to raise full-year revenue guidance to $2.85–$2.91 billion, above the $2.80 billion consensus.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179622730?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179622730","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Natera Rises 3.18% in Regular Trading, Multiple Investment Banks Significantly Raise Price Targets","media":"Market Focus","content":"<p><p>On September 17, Natera rose 3.18% in regular trading, trading at $355.63/share, with turnover of $34.66 million.</p><p>On the news front, multiple investment banks recently raised their price targets on Natera in quick succession. UBS significantly raised its target from $290 to $435 while maintaining a Buy rating, and Rothschild & Co Redburn initiated coverage with a Buy rating and a $385 price target. Earlier, RBC Capital also lifted its target from $275 to $350, maintaining an Outperform rating. The consensus mean target now stands at approximately $344.</p><p>The upgraded outlooks are underpinned by a series of commercial milestones for Natera's Signatera molecular residual disease test, including FDA approval as a companion diagnostic in muscle-invasive bladder cancer, regulatory clearance from Japan's PMDA for colorectal cancer use, and EU IVDR Class C certification across multiple solid tumor types. Additionally, the company's Q2 revenue of $752.8 million significantly beat the $661.2 million estimate, prompting management to raise full-year revenue guidance to $2.85–$2.91 billion, above the $2.80 billion consensus.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Natera Rises 3.18% in Regular Trading, Multiple Investment Banks Significantly Raise Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Natera Rises 3.18% in Regular Trading, Multiple Investment Banks Significantly Raise Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-17 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 17, Natera rose 3.18% in regular trading, trading at $355.63/share, with turnover of $34.66 million.</p><p>On the news front, multiple investment banks recently raised their price targets on Natera in quick succession. UBS significantly raised its target from $290 to $435 while maintaining a Buy rating, and Rothschild & Co Redburn initiated coverage with a Buy rating and a $385 price target. Earlier, RBC Capital also lifted its target from $275 to $350, maintaining an Outperform rating. The consensus mean target now stands at approximately $344.</p><p>The upgraded outlooks are underpinned by a series of commercial milestones for Natera's Signatera molecular residual disease test, including FDA approval as a companion diagnostic in muscle-invasive bladder cancer, regulatory clearance from Japan's PMDA for colorectal cancer use, and EU IVDR Class C certification across multiple solid tumor types. Additionally, the company's Q2 revenue of $752.8 million significantly beat the $661.2 million estimate, prompting management to raise full-year revenue guidance to $2.85–$2.91 billion, above the $2.80 billion consensus.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"","article_id":"1179622730","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179622730","pubTimestamp":1789653660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 17, Natera rose 3.18% in regular trading, trading at $355.63/share, with turnover of $34.66 million.On the news front, multiple investment banks recently raised their price targets on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc."},"translate_title":"走势警报|Natera常规交易上涨3.18%，多家投行大幅提高目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1},"content_text":"On September 17, Natera rose 3.18% in regular trading, trading at $355.63/share, with turnover of $34.66 million.On the news front, multiple investment banks recently raised their price targets on Natera in quick succession. UBS significantly raised its target from $290 to $435 while maintaining a Buy rating, and Rothschild & Co Redburn initiated coverage with a Buy rating and a $385 price target. Earlier, RBC Capital also lifted its target from $275 to $350, maintaining an Outperform rating. The consensus mean target now stands at approximately $344.The upgraded outlooks are underpinned by a series of commercial milestones for Natera's Signatera molecular residual disease test, including FDA approval as a companion diagnostic in muscle-invasive bladder cancer, regulatory clearance from Japan's PMDA for colorectal cancer use, and EU IVDR Class C certification across multiple solid tumor types. Additionally, the company's Q2 revenue of $752.8 million significantly beat the $661.2 million estimate, prompting management to raise full-year revenue guidance to $2.85–$2.91 billion, above the $2.80 billion consensus.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179622730","isCrawlerRequest":true}